EP3270962A4 - Compositions de vaccins, adjuvants et méthodes de traitement d'infections urinaires - Google Patents

Compositions de vaccins, adjuvants et méthodes de traitement d'infections urinaires Download PDF

Info

Publication number
EP3270962A4
EP3270962A4 EP16765693.3A EP16765693A EP3270962A4 EP 3270962 A4 EP3270962 A4 EP 3270962A4 EP 16765693 A EP16765693 A EP 16765693A EP 3270962 A4 EP3270962 A4 EP 3270962A4
Authority
EP
European Patent Office
Prior art keywords
vaccines
adjuvants
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16765693.3A
Other languages
German (de)
English (en)
Other versions
EP3270962A1 (fr
Inventor
Gary Eldridge
Steven M. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequoia Vaccines Inc
Original Assignee
Sequoia Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/660,523 external-priority patent/US9149521B2/en
Priority claimed from US14/800,003 external-priority patent/US9415097B2/en
Application filed by Sequoia Sciences Inc filed Critical Sequoia Sciences Inc
Publication of EP3270962A1 publication Critical patent/EP3270962A1/fr
Publication of EP3270962A4 publication Critical patent/EP3270962A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP16765693.3A 2015-03-17 2016-03-16 Compositions de vaccins, adjuvants et méthodes de traitement d'infections urinaires Withdrawn EP3270962A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/660,523 US9149521B2 (en) 2013-09-25 2015-03-17 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US201562135092P 2015-03-18 2015-03-18
US14/800,003 US9415097B2 (en) 2013-09-25 2015-07-15 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
PCT/US2016/022711 WO2016149417A1 (fr) 2015-03-17 2016-03-16 Compositions de vaccins, adjuvants et méthodes de traitement d'infections urinaires

Publications (2)

Publication Number Publication Date
EP3270962A1 EP3270962A1 (fr) 2018-01-24
EP3270962A4 true EP3270962A4 (fr) 2018-08-22

Family

ID=56919421

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16765693.3A Withdrawn EP3270962A4 (fr) 2015-03-17 2016-03-16 Compositions de vaccins, adjuvants et méthodes de traitement d'infections urinaires
EP16765794.9A Withdrawn EP3270963A4 (fr) 2015-03-17 2016-03-17 Compositions de vaccins et d'adjuvants et méthodes de traitement d'infections urinaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16765794.9A Withdrawn EP3270963A4 (fr) 2015-03-17 2016-03-17 Compositions de vaccins et d'adjuvants et méthodes de traitement d'infections urinaires

Country Status (3)

Country Link
EP (2) EP3270962A4 (fr)
CN (2) CN107405395A (fr)
WO (2) WO2016149417A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US20080131466A1 (en) * 2006-09-26 2008-06-05 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20130273149A1 (en) * 2012-04-12 2013-10-17 Ac Immune Sa Disaccharide synthetic lipid compounds and uses thereof
WO2015044886A2 (fr) * 2013-09-25 2015-04-02 Sequoia Sciences, Inc. Compositions de vaccins, adjuvants et procédés pour le traitement d'infections urinaires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US6630161B1 (en) * 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
WO2002015928A1 (fr) * 2000-08-18 2002-02-28 Medimmune, Inc. Methode d'administration d'une proteine fimh en tant que vaccin contre les infections de infections urinaires
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9669060B2 (en) * 2009-04-23 2017-06-06 Cornell University Compositions for preventing and treating uterine disease
AU2010270722B2 (en) * 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
HUE058971T2 (hu) * 2009-07-15 2022-09-28 Glaxosmithkline Biologicals Sa RSV F fehérjekészítmények és eljárások azok elõállítására
CN110339160A (zh) * 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US20080131466A1 (en) * 2006-09-26 2008-06-05 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20130273149A1 (en) * 2012-04-12 2013-10-17 Ac Immune Sa Disaccharide synthetic lipid compounds and uses thereof
WO2015044886A2 (fr) * 2013-09-25 2015-04-02 Sequoia Sciences, Inc. Compositions de vaccins, adjuvants et procédés pour le traitement d'infections urinaires

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDERSON R C ET AL: "Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 1, 1 January 2010 (2010-01-01), pages 123 - 132, XP026770794, ISSN: 0927-7765, [retrieved on 20090820], DOI: 10.1016/J.COLSURFB.2009.08.022 *
AYESHA MISQUITH ET AL: "In vitro evaluation of TLR4 agonist activity: Formulation effects", COLLOIDS AND SURFACES. B, BIOINTERFACES, vol. 113, 1 January 2014 (2014-01-01), NL, pages 312 - 319, XP055270242, ISSN: 0927-7765, DOI: 10.1016/j.colsurfb.2013.09.006 *
C. B. FOX ET AL: "Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, vol. 19, no. 10, 1 October 2012 (2012-10-01), US, pages 1633 - 1640, XP055286524, ISSN: 1556-6811, DOI: 10.1128/CVI.00235-12 *
HW MILLIE FUNG ET AL: "Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity", JOURNAL OF NANOBIOTECHNOLOGY, BIOMED CENTRAL, GB, vol. 11, no. 1, 21 December 2013 (2013-12-21), pages 43, XP021172581, ISSN: 1477-3155, DOI: 10.1186/1477-3155-11-43 *
LANGERMANN S ET AL: "VACCINATION WITH FIMH ADHESIN PROTECTS CYNOMOLGUS MONKEYS FROM COLONIZATION AND INFECTION BY UROPATHOGENIC ESCHERICHIA COLI", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 181, 1 February 2000 (2000-02-01), pages 774 - 778, XP002944650, ISSN: 0022-1899, DOI: 10.1086/315258 *
RHEA N. COLER ET AL: "Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant", PLOS ONE, vol. 6, no. 1, 26 January 2011 (2011-01-26), pages e16333, XP055030261, DOI: 10.1371/journal.pone.0016333 *
See also references of WO2016149417A1 *

Also Published As

Publication number Publication date
WO2016149558A2 (fr) 2016-09-22
CN107530418A (zh) 2018-01-02
EP3270962A1 (fr) 2018-01-24
WO2016149558A3 (fr) 2017-03-23
WO2016149417A1 (fr) 2016-09-22
EP3270963A2 (fr) 2018-01-24
EP3270963A4 (fr) 2018-08-22
CN107405395A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
EP3049104A4 (fr) Compositions de vaccins, adjuvants et procédés pour le traitement d'infections urinaires
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3390666A4 (fr) Compositions et méthodes de traitement de maladies rénales
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
EP3157565A4 (fr) Traitement d'infections polybactériennes
EP3285874A4 (fr) Compositions et méthodes pour le traitement d'infections et de maladies pulmonaires à mycobactéries
EP3182989A4 (fr) Méthodes et compositions destinées à prévenir et à traiter une maladie
EP3268007A4 (fr) Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
EP3280422A4 (fr) Compositions et méthodes de traitement d'une infection à vhb
EP3166615A4 (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d
EP3442996A4 (fr) Méthodes de traitement faisant intervenir des conjugués de chlorotoxine
ZA201702884B (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
EP3518918A4 (fr) Méthodes et compositions pharmaceutiques pour le traitement de la stéatohépatite non alcoolique
IL250596A0 (en) The composition for the treatment and prevention of urinary tract infections
EP3419638A4 (fr) Compositions et procédés de traitement de maladies infectieuses chroniques
EP3426671A4 (fr) Composés et compositions pour le traitement d'infections
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
EP3341006A4 (fr) Compositions et méthodes pour le traitement d'une lésion neurologique
EP3258908A4 (fr) Compositions et méthodes de traitement d'infections cutanées
EP3509614A4 (fr) Méthodes et compositions pour le traitement de la maladie de lafora
EP3538079A4 (fr) Compositions et méthodes pour le traitement de maladies infectieuses buccales
EP3139908A4 (fr) Formulations et procédés pour administration d'antiprogestérones par voie vaginale
EP3512550A4 (fr) Compositions et procédés pour le traitement d'infections
EP3448377A4 (fr) Méthodes pour le traitement d'une infection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20171013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180719

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7016 20060101ALI20180713BHEP

Ipc: A61K 39/02 20060101ALI20180713BHEP

Ipc: A61K 39/39 20060101ALI20180713BHEP

Ipc: A61K 39/00 20060101ALI20180713BHEP

Ipc: A61K 9/00 20060101ALI20180713BHEP

Ipc: A61K 39/108 20060101AFI20180713BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEQUOIA VACCINES, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEQUOIA VACCINES, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190219